Deep vein thrombosis on the fourth day of risperidone therapy

BMJ Case Rep. 2021 Mar 5;14(3):e239569. doi: 10.1136/bcr-2020-239569.


Deep vein thrombosis has been recognised as a complication of antipsychotic treatment and is reported to be more common with atypical antipsychotics. Risperidone is a second-generation atypical antipsychotic and there have been case reports of risperidone-associated deep vein thrombosis, most of them reporting the complication from 2 weeks to a few months of initiation of therapy. Here, we are reporting a case of deep vein thrombosis in a male patient in his early forties with paranoid schizophrenia, which presented on the fourth day of starting risperidone therapy. This case is being reported to highlight the fact that deep vein thrombosis can occur as early as fourth day of initiation of risperidone therapy, that too at a low dose (2 mg/day). The case also emphasises the importance of monitoring these patients for this rare but potentially serious adverse effect from the first day itself after initiation of a new antipsychotic.

Keywords: drugs: psychiatry; psychiatry (drugs and medicines); unwanted effects / adverse reactions.

Publication types

  • Case Reports

MeSH terms

  • Antipsychotic Agents* / adverse effects
  • Benzodiazepines
  • Humans
  • Male
  • Risperidone / adverse effects
  • Schizophrenia, Paranoid / drug therapy
  • Venous Thrombosis* / chemically induced
  • Venous Thrombosis* / drug therapy


  • Antipsychotic Agents
  • Benzodiazepines
  • Risperidone